文献速递免疫规划卫生政策与健康促进

特殊关注人群中COVID-19疫苗接种的获益-风险评估

Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.
PubMed 文献 · Vaccine · 2022-05-27

本综述总结了关于免疫功能低下、癌症、HIV感染、慢性炎症性疾病(包括自身免疫病)、原发性免疫缺陷及肾脏或肝脏疾病人群接种COVID-19疫苗的有效性、安全性和获益-风险概况的现有数据及国家卫生当局的建议,并指出需进一步大规模和长期评估以指导管理和疫苗接种策略。

要点

  • 免疫功能低下、癌症、HIV感染、慢性炎症性疾病、原发性免疫缺陷及肾脏或肝脏疾病人群感染SARS-CoV-2后重症和死亡风险增加。
  • 需更好地理解COVID-19病程及疫苗在这些脆弱人群中的有效性、安全性和获益-风险概况,以 informing 卫生政策制定者和循证疫苗接种策略。
  • 尽管已做出显著努力,仍需进一步大规模和长期评估,特别是考虑到疫苗诱导免疫减弱和SARS-CoV-2关切变异株传播激增的担忧。

核心结论

  • 需进一步大规模和长期评估以帮助指导管理和疫苗接种策略,特别是考虑到对疫苗诱导免疫减弱和SARS-CoV-2关切变异株传播激增的担忧。

研究设计与样本

  • 本综述总结了当前数据,包括国家卫生当局对上述人群COVID-19疫苗接种影响和获益-风险概况的建议。

主要发现

  • 免疫功能低下、癌症诊断、HIV感染或慢性炎症性疾病(包括自身免疫病)、原发性免疫缺陷以及肾脏或肝脏疾病人群感染SARS-CoV-2后重症和死亡风险增加。
  • 需更好地理解COVID-19病程以及COVID-19疫苗在这些脆弱人群中的有效性、安全性和获益-风险概况,以 informing 卫生政策制定者和识别循证疫苗接种策略。

局限性

  • 需进一步大规模和长期评估以帮助指导管理和疫苗接种策略,特别是考虑到对疫苗诱导免疫减弱和SARS-CoV-2关切变异株传播激增的担忧。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Several population groups display an increased risk of severe disease and mortality following SARS-CoV-2 infection. These include those who are immunocompromised (IC), have a cancer diagnosis, human immunodeficiency virus (HIV) infection or chronic inflammatory disease including autoimmune disease, primary immunodeficiencies, and those with kidney or liver disease. As such, improved understanding of the course of COVID-19 disease, as well as the efficacy, safety, and benefit-risk profiles of COVID-19 vaccines in these vulnerable groups is paramount in order to inform health policy makers and identify evidence-based vaccination strategies. In this review, we seek to summarize current data, including recommendations by national health authorities, on the impact and benefit-risk profiles of COVID-19 vaccination in these populations. Moving forward, although significant efforts have been made to elucidate and characterize COVID-19 disease course and vaccine responses in these groups, further larger-scale and longer-term evaluation will be instrumental to help further guide management and vaccination strategies, particularly given concerns about waning of vaccine-induced immunity and the recent surge of transmission with SARS-CoV-2 variants of concern.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Moss P, Berenbaum F, Curigliano G, et al. Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest. Vaccine. 2022. PMID: 35718592. doi:10.1016/j.vaccine.2022.05.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。